Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label phase 2 study of MBX-8025 in homozygous familial hypercholesterolemia
2014-004856-68Phase 2Completed
- Sponsor
- CymaBay Therapeutics
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of seladelpar in familial hypercholesterolemia (FH), sponsored by CymaBay Therapeutics. Primary endpoint: Serum LDL-C change. Started Jan 2015; status: completed.
02
Drugs
seladelpar
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2014-004856-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004856-68.